This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human CD20 / MS4A1 Full Length Protein, His Tag (HEK293) (SPR verified)
catalog :
CD0-H52H3
quantity :
500 ug, 100 ug, 20 ug
price :
6800 USD, 2990 USD, 850 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
CD0-H52H3
product name :
Human CD20 / MS4A1 Full Length Protein, His Tag (HEK293) (SPR verified)
quantity :
500 ug, 100 ug, 20 ug
price :
6800 USD, 2990 USD, 850 USD
quantity & price :
$850/20ug,$2990/100ug,$6800/500ug
target :
CD20
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human CD20 Full Length, His Tag (HEK293) (SPR verified) (CD0-H52H3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>85% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human CD20 Full Length, His Tag (HEK293) (SPR verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 85%.
Formulation :
Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant. This product is not suitable for cell based experiments due to cytotoxicity of DDM. .
DDM and CHS are INDISPENSABLE to keep CD20 soluble and active, under no circumastance should you remove DDM and CHS. .
DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer. .
If glycerol is not compatible to your application, remove glycerol just before immediate experiment, and NEVER store glycerol-free protein solution. .
Contact us for customized product form or formulation.
Storage :
Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● The product MUST be stored at -70°C or lower upon receipt;
● -70℃ for 3 months under sterile conditions.
Background :
B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
References :
(1) Walport M, et al., 2008, Janeway's Immunobiology (7th ed.). New York: Garland Science.
(2) Bonilla FA, Bona CA., 1996, Textbook of Immunology. Boca Raton: CRC. p. 102.
(3) Cragg MS., 2005., Curr. Dir. Autoimmun. 8: 140–74.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments